Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Caribou Biosciences (CRBU) Non Operating Income (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Non Operating Income for 6 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Non Operating Income fell 58.09% to $1.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.8 million, a 89.57% decrease, with the full-year FY2025 number at -$331000.0, down 101.89% from a year prior.
  • Non Operating Income was $1.4 million for Q4 2025 at Caribou Biosciences, up from -$6.5 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $5.8 million in Q2 2024 to a low of -$6.5 million in Q2 2025.
  • A 5-year average of $2.0 million and a median of $2.7 million in 2021 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: plummeted 2940.96% in 2021, then skyrocketed 10931.25% in 2022.
  • Caribou Biosciences' Non Operating Income stood at $2.2 million in 2021, then soared by 62.84% to $3.7 million in 2022, then fell by 14.46% to $3.1 million in 2023, then increased by 7.86% to $3.4 million in 2024, then tumbled by 58.09% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Non Operating Income are $1.4 million (Q4 2025), -$6.5 million (Q2 2025), and $3.4 million (Q4 2024).